Replies to post #202549 on Biotech Values

[mr_o]

In a scenario where a patents are found to be valid after a generic version is launched, what is the standard protocol? Is the generic forced off the market until the appropriate time?

[Bickema]

TEVA and APP Pharma Angiomax generic can enter the market in 2019

http://www.themedicinescompany.com/investors/sec-filing/7844757/aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTc4NDQ3NTcmRFNFUT0xJlNFUT0mU1FERVNDPVNFQ1RJT05fQk9EWSZleHA9JnN1YnNpZD01Nw%3D%3D

Under the License Agreement, the Company grants Teva a non-exclusive license under the Litigated Patents to sell a generic bivalirudin for injection product under a Teva ANDA (the “Teva Product”) in the United States beginning June 30, 2019 or earlier under certain conditions. Under the License Agreement, Teva will be required to pay the Company royalties on gross profits of its sales of the Teva Product under certain circumstances.

http://ir.themedicinescompany.com/mobile.view?c=122204&v=203&d=1&id=1651267

License by MDCO The settlement agreement includes a license by MDCO to APP and an affiliate of APP under which APP may launch a generic bivalirudin product in the U.S. on May 1, 2019. In certain limited circumstances, this license to APP could become effective prior to May 1, 2019 and could include an authorized generic bivalirudin product supplied by MDCO.

This a potential sale of the company may be whats preventing MDCO from signing a partnership with Eagle

[Bickema]

Pfizer should just acquire MDCO maybe get a discount on potential damages while avoiding litigation

Sounds like their CEO would welcome that

One of the world's greatest drug companies is on the end of this discussion. That's called Pfizer. And we have great respect for them. We're partners of theirs. And to have such a conversation on a conference call might be a bit premature at this stage.